Avita Medical (NASDAQ:RCEL) and Coloplast A/S (OTCMKTS:CLPBY) Critical Analysis

Coloplast A/S (OTCMKTS:CLPBY) and Avita Medical (NASDAQ:RCEL) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Volatility & Risk

Coloplast A/S has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Comparatively, Avita Medical has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500.

Profitability

This table compares Coloplast A/S and Avita Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coloplast A/S	9.68%	39.27%	11.54%
Avita Medical	-56.96%	N/A	-78.53%

Institutional & Insider Ownership

27.7% of Avita Medical shares are held by institutional investors. 2.2% of Avita Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Coloplast A/S and Avita Medical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coloplast A/S	$4.13 billion	3.75	$538.49 million	$0.19	36.21
Avita Medical	$75.63 million	5.33	-$48.59 million	($1.44)	-9.10

Coloplast A/S has higher revenue and earnings than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than Coloplast A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Coloplast A/S and Avita Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coloplast A/S	1	1	0	1	2.33
Avita Medical	1	1	5	0	2.57

Avita Medical has a consensus price target of $12.20, suggesting a potential downside of 6.87%. Given Avita Medical’s stronger consensus rating and higher probable upside, analysts plainly believe Avita Medical is more favorable than Coloplast A/S.

Summary

Coloplast A/S beats Avita Medical on 8 of the 15 factors compared between the two stocks.

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

About Avita Medical

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.